Traders should monitor for potential downward pressure on shares, especially if this selling follows weak recent performance or precedes an earnings release. The absence of buying and concentration of sales among senior executives may signal lack of near-term confidence at current valuations.
Price Chart
Executive Summary
Seven executives at Teva Pharmaceutical exercised stock derivatives and several conducted open-market sales totaling approximately $2.13 million in the past week. The transactions are primarily non-cash exercises, but significant insider selling by multiple C-suite executives suggests profit-taking at current price levels.
Key Financial Metrics
Key Facts
- Multiple C-suite executives sold shares in open-market transactions on 2026-03-05.
- Total open-market sales amounted to $2,132,043 across five insiders.
- All sales occurred at $31.6684 per share, indicating coordinated timing.
- Selling executives include EVPs of Global Operations, Europe Commercial, U.S. Commercial, Interim Chief Legal Officer, and others.
- All sales were preceded by derivative exercises at $0 cost, suggesting option expirations or vesting events.
- No open-market purchases were reported — only sales and non-cash derivative exercises.
Financial Impact
$2.13 million in insider selling over 7 days
Risk Factors
- Insider selling could accelerate if stock remains above $31–32 range.
- Perception of negative sentiment may impact investor confidence, particularly if no offsetting corporate news emerges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-TEVA-1773087757920 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.53 (+8.75%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.53 (+7.54%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.53 (+5.44%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.53 (+8.48%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.53 (+3.75%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.53 (+3.75%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.53 (+9.38%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.53 (+13.56%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.53 (+12.91%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.53 (+13.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access